The Commission for Technology and Innovation (CTI) is promoting Swiss start-ups during applied research projects which are carried out in cooperation with leading Swiss universities. Yesterday, the CTI awarded ReFlow Therapeutics a grant of worth CHF 823,925 to complete their current project; "Development and non-clinical verification of a diagnostic and therapeutic approach to treat microvascular obstructions in heart attack patients." The project runs over the next 18 months.
Dominik Obrist, who is heading the project, said: "We are excited to start the cooperation with ReFlow to better understand microvascular obstructions in the coronary circulation. The interdisciplinary research consortium brings together unique capabilities in magnetic resonance imaging (MRI), non-clinical research and circulatory modelling which will be instrumental to gain new insights into the coronary microcirculation".
"The CTI project will enable us to develop solid MRI protocols and non-clinical models to document the value of the ReFlow Controlled Flow Infusion (CoFI) technology. We are very pleased to work with leading Swiss scientists to document the benefit of our arterial technology to diagnose and treat microvascular obstructions", said Jon H. Hoem, ReFlow'sCEO and Co-Founder.
ReFlow’s project is run in cooperation with Dominik Obrist, professor at University of Bern, ARTORG Center of Biomedical Engineering Research, Cardiovascular Engineering, Urs Moser, professor at the NTB Interstate University of Applied Sciences Buchs, Sebastian Kozerke, professor at University and ETH Zurich, Inst. for Biomedical Engineering and Nikola Cesarovic from the University Hospital Zürich, Division of Surgical Research.
About ReFlow Therapeutics AG
Based in Baar in Canton Zug, ReFlow Therapeutics is a medtech startup developing technologies for novel diagnostic and therapeutic approaches for microvascular obstructions in heart attack patients. ReFlow is currently developing the CoFI console and rapid exchange (RX) catheter for non-clinical trials to generate data for its regulatory design dossiers. The Company targets to complete these development stages over the next 18 months and will provide regular updates on the progress of the Company.